Oppenheimer initiated coverage on shares of Quince Therapeutics (NASDAQ:QNCX – Free Report) in a research report report published on Wednesday, MarketBeat reports. The brokerage issued an outperform rating and a $82.00 price objective on the stock.
Several other research analysts have also issued reports on QNCX. Weiss Ratings lowered shares of Quince Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 1st. Zacks Research raised Quince Therapeutics to a “hold” rating in a research note on Wednesday, June 24th. Lifesci Capital raised Quince Therapeutics to a “strong-buy” rating in a research note on Monday, June 29th. Cantor Fitzgerald initiated coverage on Quince Therapeutics in a report on Tuesday, June 23rd. They issued an “overweight” rating and a $80.00 price objective for the company. Finally, Wall Street Zen upgraded Quince Therapeutics from a “sell” rating to a “hold” rating in a research report on Sunday, May 17th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, five have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $568.40.
View Our Latest Research Report on QNCX
Quince Therapeutics Price Performance
Quince Therapeutics (NASDAQ:QNCX – Get Free Report) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.59) EPS for the quarter, topping analysts’ consensus estimates of ($26.00) by $25.41. On average, research analysts expect that Quince Therapeutics will post -2.72 EPS for the current fiscal year.
Hedge Funds Weigh In On Quince Therapeutics
Institutional investors and hedge funds have recently bought and sold shares of the stock. Nantahala Capital Management LLC boosted its stake in shares of Quince Therapeutics by 21.6% during the third quarter. Nantahala Capital Management LLC now owns 3,073,729 shares of the company’s stock valued at $5,010,000 after purchasing an additional 545,427 shares during the period. Adage Capital Partners GP L.L.C. purchased a new position in shares of Quince Therapeutics in the fourth quarter worth $7,538,000. Vanguard Group Inc. raised its holdings in Quince Therapeutics by 21.3% during the 3rd quarter. Vanguard Group Inc. now owns 1,763,387 shares of the company’s stock valued at $2,874,000 after buying an additional 309,349 shares during the last quarter. Millennium Management LLC boosted its position in Quince Therapeutics by 1,152.9% during the 3rd quarter. Millennium Management LLC now owns 1,386,776 shares of the company’s stock valued at $2,260,000 after buying an additional 1,276,094 shares during the period. Finally, Almitas Capital LLC boosted its position in Quince Therapeutics by 88.0% during the 4th quarter. Almitas Capital LLC now owns 930,134 shares of the company’s stock valued at $3,116,000 after buying an additional 435,356 shares during the period. 30.75% of the stock is currently owned by institutional investors.
About Quince Therapeutics
Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions.
Read More
- Five stocks we like better than Quince Therapeutics
- Chevron’s Strong Quarter Shows Why It Still Leads the Energy Sector
- Amazon’s Earnings Beat Shows Why AWS Is Back at the Center of the Bull Case
- Apple’s Record Quarter Could Not Outrun Its Guidance Problem
- McKesson’s Compounding Keeps Adding Up
Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
